Beyond THC and CBD: Why Minor Cannabinoids Are Getting More Attention
For years, conversations about cannabis have largely centered on two compounds: THC and CBD. THC is best known for producing the intoxicating effects associated with cannabis, while CBD has gained attention for its non-intoxicating properties and potential medical applications.
But cannabis is a chemically complex plant, and those two cannabinoids represent only part of the picture.
Researchers have identified well over 100 cannabinoids in cannabis, including compounds that occur naturally in much smaller quantities. These are often described as minor cannabinoids. As laboratory methods improve, scientists are becoming better equipped to detect, isolate, measure, and study them.
That progress is opening new questions for medical research and the cannabis industry. Could lesser-known cannabinoids eventually contribute to new treatments? How can producers measure these compounds accurately? And what should consumers understand when they encounter products marketed around emerging cannabinoids?
The answers are still developing, but the science behind minor cannabinoids is an important area to watch.
What Are Minor Cannabinoids?
Cannabinoids are chemical compounds that interact with biological systems in the human body. THC and CBD are the best-known examples, but they are not the only ones produced by the cannabis plant.
Minor cannabinoids are generally those that occur in lower concentrations than the major cannabinoids. The term describes their relative abundance, not necessarily their importance or potential activity.
Some examples include cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and cannabidivarin (CBDV). These compounds have different chemical structures and may interact with the body differently.
Their presence can vary depending on the cannabis variety, growing conditions, maturity of the plant, processing methods, and storage conditions.
For researchers, this chemical diversity presents both an opportunity and a challenge. The plant contains a wide range of compounds worth investigating, but understanding what each one does requires careful laboratory analysis and appropriately designed studies.
A compound’s presence in cannabis does not automatically mean it has a proven medical benefit.
Why Are Researchers Paying More Attention Now?
One reason minor cannabinoids are receiving greater attention is the development of more sensitive analytical techniques.
A review published in Phytochemical Analysis in 2026 examined advances in the extraction and measurement of minor phytocannabinoids. The authors highlighted how improved analytical methods are helping researchers detect and quantify compounds that were previously more difficult to study.
That matters because scientists cannot reliably investigate a compound if they cannot measure it accurately.
Better analytical methods can help researchers identify individual cannabinoids, determine their concentrations in plant material, assess the purity of extracts, and compare samples across experiments.
These techniques may also help laboratories identify differences between products that otherwise appear similar.
For the cannabis industry, more precise testing can contribute to better product characterization and quality control. For medical researchers, it can help establish a more reliable foundation for investigating possible therapeutic applications.
You can read the review through Wiley’s Phytochemical Analysis journal.
CBG: One of the Cannabinoids Under Investigation
Cannabigerol, commonly known as CBG, is one of the minor cannabinoids attracting interest from researchers and product developers.
CBG is sometimes discussed as a precursor in the plant’s cannabinoid production pathways. During plant development, related acidic cannabinoid compounds can be converted through enzymatic and chemical processes into other cannabinoids.
This chemistry makes CBG interesting from both a botanical and manufacturing perspective.
Researchers are investigating CBG’s biological activity and possible medical applications, but the available evidence remains much less developed than the public attention surrounding the compound might suggest. Early laboratory findings do not establish that a CBG product will treat a particular condition in people.
For consumers, the important distinction is between a compound that scientists are investigating and a treatment that has been demonstrated to work in well-controlled human studies.
CBG may become an important subject in future research, but consumers should be cautious about products that promise specific medical outcomes without strong clinical evidence.
CBN, CBC, and Other Emerging Compounds
CBN, or cannabinol, is another cannabinoid that appears in cannabis products and attracts consumer interest. It can form as THC degrades over time through exposure to factors such as oxygen, light, and heat.
CBN is often marketed in connection with sleep, but the strength of the evidence for specific sleep-related claims remains limited. Consumers should not assume that a product containing CBN will reliably improve sleep simply because the compound appears in its ingredient list.
CBC, or cannabichromene, is another naturally occurring cannabinoid under investigation. Like CBG and CBN, it has been studied for various biological effects, but more research is needed to understand its clinical relevance.
Other compounds, including CBDV, are also being investigated for possible therapeutic applications.
The broader point is that minor cannabinoids are not a single category of substances with one shared effect. Each compound has its own chemistry, and evidence about one cannabinoid cannot automatically be applied to another.
From Laboratory Research to Medical Treatments
One of the biggest questions surrounding minor cannabinoids is whether any will eventually become part of approved medical treatments.
The process of developing a medicine is much more demanding than identifying a compound with interesting properties.
Researchers typically begin by investigating a substance’s chemical characteristics and biological activity. Laboratory studies may help identify mechanisms worth exploring, while animal studies can provide additional early evidence. Human clinical trials are then needed to determine whether a treatment is effective and sufficiently safe for a specific use.
Even promising early findings can fail to translate into meaningful benefits for patients.
Dose, formulation, absorption, metabolism, side effects, and interactions with other medications all matter. Researchers also need to determine whether a compound provides meaningful benefits compared with existing treatments.
A 2025 publication indexed by PubMed discussing the development of cannabis-based botanical drugs highlighted continuing gaps in preclinical and clinical evidence, particularly for minor cannabinoids. It also described the scientific and regulatory challenges involved in turning complex plant-derived products into medicines.
Read more through PubMed’s discussion of botanical cannabis drug development.
This is an important reminder that scientific interest is only the beginning. Developing a reliable medical treatment requires evidence, reproducibility, quality controls, and appropriate regulatory review.
Why Extraction and Testing Matter
As interest in minor cannabinoids grows, extraction and analytical testing are becoming increasingly important to the cannabis industry.
Cannabinoids occur in varying concentrations throughout the plant, and producing an extract with a particular chemical profile can require specialized processing and careful quality control.
Manufacturers must consider how extraction methods affect the compounds they want to preserve, how unwanted materials are removed, and how the finished product is tested.
Analytical laboratories then help determine which cannabinoids are present and in what concentrations. Depending on the product and applicable regulations, testing may also assess contaminants and other quality or safety characteristics.
Accurate testing is particularly important when a product is marketed around a minor cannabinoid. If a label claims that a product contains a particular amount of CBG or CBN, reliable analytical methods are necessary to substantiate that claim.
Better measurement can also help manufacturers evaluate consistency between batches. That consistency matters to consumers, retailers, and researchers trying to compare products or understand their effects.
However, a more precise cannabinoid profile does not automatically make a product more effective. Testing tells us more about what is in a product; clinical evidence is needed to determine what that product does in the human body.
Will Minor Cannabinoids Change the Way Cannabis Products Are Made?
They may influence how some products are developed, although the pace and direction of change will depend on scientific evidence, consumer demand, manufacturing capabilities, and regulatory requirements.
Traditionally, cannabis products have often been described primarily by strain name, THC percentage, or CBD content. More detailed cannabinoid profiles may provide another way to characterize products.
Manufacturers could increasingly differentiate products by their measured cannabinoid composition rather than relying only on familiar strain names or broad marketing descriptions.
This could encourage more sophisticated testing, more precise formulation, and better communication about product contents.
It may also create opportunities for collaboration between cultivators, extraction specialists, analytical laboratories, and researchers. Cultivators can work to understand the chemical characteristics of different plant varieties, processors can investigate extraction and formulation techniques, and laboratories can help verify the resulting profiles.
Still, these developments should be approached with realistic expectations. A more detailed label can help consumers compare products, but it does not establish that one cannabinoid profile is medically superior to another.
What About the Entourage Effect?
The entourage effect is a term used to describe the proposed idea that cannabis compounds may influence one another’s effects when present together.
The concept often appears in discussions about cannabinoids and terpenes. Some consumers believe that a product containing multiple compounds may provide a different experience from one containing a single isolated cannabinoid.
This is a legitimate area of scientific interest, but it should not be treated as a universal explanation for how cannabis works.
The extent to which different compounds interact, whether those interactions are clinically meaningful, and how those effects vary by product and individual remain areas of investigation.
A product containing several cannabinoids is not automatically more effective than a product containing one. Demonstrating a meaningful interaction requires controlled research that compares appropriate formulations and outcomes.
For consumers, the most useful approach is to view the entourage effect as a research concept rather than a guarantee of enhanced results.
What Should Consumers Look for on Product Labels?
As cannabis products become more specialized, reading labels carefully becomes increasingly important.
Consumers may see information about THC, CBD, CBG, CBN, and other cannabinoids, along with terpene profiles and total potency. These details can help explain a product’s chemical composition, but they should be interpreted carefully.
Start by checking the amounts and concentrations listed for the product. Pay attention to serving sizes where applicable, because the total amount of a cannabinoid in a package is not necessarily the amount in one serving.
It is also helpful to consider the product format. Flower, vapes, concentrates, tinctures, and edibles differ in how they are consumed and how their effects may develop.
Look for products tested in accordance with the applicable state requirements, and ask the dispensary team to explain unfamiliar terminology.
Most importantly, be skeptical of sweeping health claims. The presence of a newly popular cannabinoid does not mean a product has been proven to help with pain, anxiety, sleep, inflammation, or another medical concern.
Patients considering cannabis for a medical purpose should discuss their options with a qualified healthcare provider, particularly if they take prescription medications.
What This Means for the Future of Cannabis Research
The growing interest in minor cannabinoids reflects a broader effort to understand cannabis as a complex plant rather than a source of only THC and CBD.
Advances in analytical chemistry are helping scientists identify compounds more precisely. Improved extraction and testing methods may support more consistent products and better-designed studies. Meanwhile, researchers are continuing to investigate which cannabinoids have meaningful biological effects and whether those effects could eventually translate into useful treatments.
Important challenges remain. Researchers need more reliable data on individual compounds, clearer information about appropriate doses and formulations, and well-designed clinical trials that evaluate both benefits and risks.
The industry also faces the challenge of communicating emerging science responsibly. New discoveries can generate excitement, but premature medical claims can leave consumers with unrealistic expectations.
The most valuable progress will come from connecting laboratory findings with reproducible research, transparent product information, and evidence that genuinely helps people make better decisions.
How KindCare Approaches Cannabis Education
At KindCare, we believe understanding cannabis starts with understanding what is actually in a product.
THC and CBD remain important when comparing cannabis products, but they are not the entire story. Cannabinoid profiles, product formats, potency, and other chemical characteristics can all be relevant when learning about available options.
As research develops, education can help consumers separate established facts from early-stage findings and marketing claims.
Our team can help explain product labels, cannabinoid terminology, and differences between product types. For medical questions, we encourage patients to work with qualified healthcare providers who can evaluate their individual circumstances.
We believe the future of cannabis should include better information, more consistent quality, and an honest understanding of what research has—and has not—demonstrated.
Final Thoughts
Minor cannabinoids are becoming an important area of cannabis research, thanks in part to improvements in the techniques scientists use to identify and measure them.
Compounds such as CBG, CBN, CBC, and CBDV may offer valuable avenues for future investigation. But scientific interest should not be confused with proof of a medical benefit.
For consumers, the best approach is to stay curious while remaining critical of exaggerated claims. Read labels, ask questions, understand the limits of current evidence, and seek professional medical guidance when considering cannabis for a health concern.
For the cannabis industry, the opportunity is to turn improved scientific understanding into better testing, more transparent products, and responsible communication.
Editorial note: This article is educational and is not a substitute for professional medical advice. Research into minor cannabinoids is ongoing, and evidence may change as new studies become available.